Adding drug to chemotherapy following colon cancer surgery does not improve disease-free survival
Adding the drug cetuximab to a regimen of drugs used for the treatment of patients following surgery for stage III colon cancer did not result in improved disease-free survival, according to a study in the April 4 issue of JAMA.
Patients who have surgery for removal of stage III colon cancer have a 50 percent chance of cure. Multiple trials have established the benefit of chemotherapy after surgery in reducing the recurrence risk. "Specifically, [the drugs] leucovorin, fluorouracil, and oxaliplatin (FOLFOX or slightly different method, FLOX) provides significant benefit in both disease-free and overall survival compared with the prior standard of fluorouracil and leucovorin," according to background information in the article.
In the setting of metastatic colorectal cancer, the drugs cetuximab and panitumumab, alone and in combination with chemotherapy, have provided additional benefit to that obtained with chemotherapy alone. "This benefit, however, is limited to patients with tumors expressing the wild-type [a strain used as a standard reference to compare any mutant derivatives] form of the gene KRAS as opposed to those with the mutated form of KRAS," the authors write.
Steven R. Alberts, M.D., of the Mayo Clinic, Rochester, M inn., and colleagues conducted a study to assess the potential benefit of cetuximab added to the modified sixth version of the FOLFOX regimen (mFOLFOX6) in patients with resected stage III wild-type KRAS colon cancer. Patient enrollment began February 2004 and was permanently halted on November 25, 2009, after the second planned interim analysis demonstrated a low probability that disease-free survival of the cetuximab group would surpass that of the mFOLFOX6-only group. A total of 2,686 patients comprised this analysis cohort (1,863 patients with wild-type KRAS, 717 patients with mutated KRAS, and 106 patients with indeterminate KRAS). The primary randomized comparison was 12 biweekly cycles of mFOLFOX6 with and without cetuximab. Median follow-up was 28 months.
The researchers found that the trial demonstrated no benefit when adding cetuximab. Three-year disease-free survival for mFOLFOX6 alone was 74.6 percent vs. 71.5 percent with the addition of cetuximab in patients with wild-type KRAS, and 67.1 percent vs. 65.0 percent in patients with mutated KRAS, with no evidence of benefit in any individual subgroup. Also, both time-to-recurrence and overall survival were not significantly different between treatment groups.
"Among all patients, grade 3 or higher adverse events (72.5 percent vs. 52.3 percent) and failure to complete 12 cycles (33 percent vs. 23 percent) were significantly higher with cetuximab," the authors write. "Increased toxicity and greater detrimental differences in all outcomes were observed in patients aged 70 years or older."
The researchers add that the reasons for the lack of benefit of mFOLFOX6 with cetuximab in the adjuvant setting remain unclear.
"In this randomized phase 3 trial for patients with resected stage III colon cancer expressing wild-type KRAS mutations, the addition of cetuximab to mFOLFOX6 did not improve disease-free or overall survival in contradistinction to the original study of cetuximab combined with FOLFOX in metastatic colorectal cancer," the authors write. "New approaches are needed to identify drugs that may be of benefit in adjuvant therapy, because as shown in our trial promising activity in the metastatic setting did not translate into adjuvant therapy benefit and underscores the importance of performing clinical trials."
In an accompanying editorial, Neil H. Segal, M.D., Ph.D., and Leonard B. Saltz, M.D., of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, write that although the negative results of this trial are surprising, this pattern has been observed before.
"The inescapable conclusion is that efficacy in the metastatic setting does not reliably predict efficacy in the adjuvant setting. The role of adjuvant chemotherapy does not involve treating the tumor that the surgeon has removed, but rather attempts to eradicate whatever occult micrometastatic disease may still be present after surgery. If there are no micrometastases, surgery is curative and adjuvant chemotherapy is unnecessary. If micrometastases are present, the long-term health of the patient will depend on whether the chemotherapy can destroy all remaining micrometastases."
More information: JAMA. 2012;307:1383-1393.
Provided by JAMA and Archives Journals
- Drug that helps metastatic colon cancer of no benefit in less advanced tumors Jun 07, 2010 | not rated yet | 0
- Colorectal cancer patients with gene mutation show better response to cancer agent Oct 26, 2010 | not rated yet | 0
- Cetuximab did not add significant benefit to NORDIC FLOX regimen in first line treatment of mCRC Oct 12, 2010 | not rated yet | 0
- New recommendations issued for use of cetuximab in colon cancer therapy Jul 16, 2010 | not rated yet | 0
- Cost-effectiveness of cetuximab in metastatic colorectal cancer Aug 08, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer 13 hours ago | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer 13 hours ago | not rated yet | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer 16 hours ago | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer 17 hours ago | 5 / 5 (1) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer 17 hours ago | 5 / 5 (3) | 0
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
16 hours ago | 5 / 5 (3) | 0 |
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
11 hours ago | 3 / 5 (2) | 0 |
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
13 hours ago | 3.7 / 5 (3) | 0 |
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
14 hours ago | 5 / 5 (4) | 0 |
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
16 hours ago | 4 / 5 (2) | 2
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.
18 hours ago | not rated yet | 2